Aap Implantate Ag · XETR:AAQ1
Aap Implantate — German Equity Forum 2016
17 slides from Aap Implantate's conference presentation, Nov 22, 2016
Slide 1: aap Implantate AG Corporate Presentation
aap Implantate AG Corporate Presentation German Equity Forum 2016 Frankfurt am Main, November 22, 2016 Bruke Seyoum Alemu, CEO Marek Hahn, CFO
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: aap Company Overview
aap Company Overview German based international MedTech company Development, manufacturing and marketing of trauma products for orthopaedics Listed in Frankfurt, Germany, Prime standard (XETRA: AAQ) Customers are hospitals, distributors and global companies worldwide Sales 2015: EUR 12.3 m
Slide 4: Our Aspiration
Our Aspiration Making trauma treatment better and cost-effective Challenges in trauma Simplify implantation as well as explantation Prevent surgical site infections Avoid second operations Our response to the challenges Address the challenges through innovations and create a sustainable valu
Slide 5: Our Roadmap for Value Creation
Our Roadmap for Value Creation Transformational roadmap Transformation through divestiture Transformation through innovation Divestiture Innovation In the last years we have In the last years we have been executed diverse divestitures to developing exciting platform become a pure player in t
Slide 6: Transformation Through Innovation
Transformation Through Innovation Clear objectives Clear innovation objectives Address unmet needs Enable differentiation Build strong intellectual property portfolio Provide strategic fit to aspiration Ensure cost-effective technical feasibility Fulfil key market regulatory approvals
Slide 7: Transformation Through Innovation: Meeting clear objectives
Transformation Through Innovation Meeting clear objectives Innovation Objectives Platform Technologies Resorbable Coated Magnesium LOQTEQ® Silver Coating Technology Implants Technology Infection prevention with anti-bacterial Address unmet needs One step variable locking compression Resorbable metal
Slide 8: Platform Technology – LOQTEQ
Platform Technology – Value based innovation Market Need Innovative Solution Efficient and minimal invasive surgery ✓ Angular stable compression in one step Angular stable locking and compression ✓ High and sustainable stability High stability of screw-plate-connection As few surgical steps as
Slide 9: Platform Technology – Silver Coating
Platform Technology – Silver Coating Value based innovation Unmet Need Innovative Solution Infection prevention for medical devices Surgical Site Infection (SSI) ✓ Prevention of bacterial colonization ✓ Platform technology with broad application Biofilm formed on an TiAl6V4 ✓ Very high efficacy (in
Slide 10: Platform Technology – Magnesium Implants
Platform Technology – Magnesium Implants Value based innovation Unmet Need Innovative Solution Biocompatible and biodegradable metal implants Disadvantages of currently used metallic implants ✓ Bioabsorbable implants Need of second surgery for implant removal ✓ Platform technology with broad appli
Slide 11: aap – Roadmap
aap – Roadmap Unique, innovative, addressing unmet needs 11
Slide 12: Financial Figures 9M/2016
Financial Figures 9M/2016 (in EUR million) Sales 9M/2016 9M/2015 Change Europe and North America 5.1 3.4 +49% Other 3.7 6.5 -42% Total Sales 8.8 9.9 -11% EBITDA 9M/2016 9M/2015 Change EBITDA -5.3 -4.5 -19% One-time effects 0.8 0.2 > +100% Recurring EBITDA -4.5 -4.3 -6% Further Figures 09/30/2016 09/
Slide 13: Accelerated Path to Profitable Growth
Accelerated Path to Profitable Growth aap Trauma aap Silver High growth momentum in Europe Coating technology as a catalyst to and North America through own own trauma portfolio sales organization Co-development projects and Accelerated access to level-1 and -2 license deals with global medt
Slide 14: aap – Sum of the Parts
aap – Sum of the Parts aap Trauma aap Silver Strong IP, comprehensive portfolio Technology addresses unmet need Strong LOQTEQ® sales growth, CAGR Strong IP, leading platform technology 2011-2015 > 100%; Sales 2015: EUR 10.8 with a wide range of applications million Valuation: external asse
Slide 15: The New aap – Pure Trauma Company
The New aap – Pure Trauma Company Why invest in aap? Comprehensive IP protected platform technologies LOQTEQ® Technology, Silver Coating Technology, Resorbable Coated Magnesium Implants Technology Comprehensive product portfolio CE, FDA and SFDA approved; indication coverage > 90% in mainstr
Slide 16: Shareholder Structure
Shareholder Structure (As of 11/22/2016, shareholdings in aap ≥ 3%) High degree of stability with a base of long-term oriented investors No significant changes within FY/2016* Market Cap of approx. EUR 40 million Total number of bearer shares: 30,832,156 13.30% Ratio Capital Management B.V., N
Slide 17: aap Implantate AG contact details
aap Implantate AG Lorenzweg 5 • 12099 Berlin • Germany www.aap.de Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: 17